Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 12/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 12/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.36 |
| ▸ | HTR2C | P28335 | 2/20 | 0.35 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.33 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.33 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL274220 | 0.86 | SLC6A2 (0.43) | SLC6A2SLC6A4GLAPOLBGAA | |
| SCHEMBL2201714 | 0.81 | SLC6A2 (0.41) | SLC6A2SLC6A4GLAPOLBGAA | |
| SCHEMBL4929501 | 0.76 | SLC6A4 (0.41) | SLC6A2SLC6A4GLAPOLBGAA | |
| SCHEMBL27726984 | 0.73 | GLA (0.40) | SLC6A2SLC6A4GLAPOLBGAA | |
| SCHEMBL13122958 | 0.71 | GAA (0.55) | GLAPOLBGAATSHRNR1H2 | |
| SCHEMBL14321224 | 0.70 | HTR2C (0.61) | SLC6A2SLC6A4GLAPOLBGAA | |
| SCHEMBL444847 | 0.67 | SLC6A4 (0.33) | SLC6A2SLC6A4SLC6A3HTR2C | |
| SCHEMBL15337708 | 0.67 | SYK (0.48) | SLC6A2SLC6A4GLAPOLBGAA | |
| SCHEMBL444816 | 0.67 | SLC6A4 (0.35) | SLC6A2SLC6A4SLC6A3HTR2C | |
| SCHEMBL27651424 | 0.67 | SLC6A4 (0.43) | SLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7977338-B2 | Phenylacetamides being FLT3 inhibitors | NOVARTIS AG (CH) | 2011-07-12 | — | — | US | disclosed |
| US-20100075980-A1 | Phenylacetamides being FLT3 Inhibitors | NOVARTIS AG (CH) | 2010-03-25 | — | — | US | disclosed |
| EP-2074125-A1 | PHENYLACETAMIDES USEFUL AS PROTEIN KINASE INHIBITORS | Novartis Ag (CH) | 2009-07-01 | — | — | EP | disclosed |
| WO-2008046802-A1 | PHENYLACETAMIDES USEFUL AS PROTEIN KINASE INHIBITORS | NOVARTIS AG (CH) | 2008-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100075980-A1 | Phenylacetamides being FLT3 Inhibitors | FLT3, JAK2, ABL1 | SLC6A2 4788/4885SLC6A4 4567/4885GLA 3484/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.